Valeant Makes Its First Acquisition Move Of The Year, In Dermatology
This article was originally published in The Pink Sheet Daily
Valeant Pharmaceuticals will continue its march into dermatology with the acquisition of PreCision Dermatology for $475 million in cash plus milestones. The deal represents a bolt-on opportunity for Valeant, which will leverage its existing infrastructure to sell PreCision’s products.
You may also be interested in...
The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
A Phase III trial testing dapagliflozin in chronic kidney disease patients with and without diabetes was stopped early following a recommendation from an independent data monitoring committee.